Loading...
 

Volume 33, Issue 4, December 2022



Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2022;33(4):444-8
Successful Treatment of Systemic Lupus Erythematosus-Associated Thrombocytopenia with Eltrombopag: A Report of Two Cases and Literature Review
Authors Information

Division of Rheumatology, Department of Internal Medicine, Pamukkale University Faculty of Medicine, Denizli, Turkey

F Ulutas, ZD Ök, U Karasu, V Çobankara

Abstract

Thrombocytopenia is one of the common haematological manifestations, occurring in 7% to 30% of systemic lupus erythematosus (SLE) patients. Immune thrombocytopenia (ITP) may occur in variable pathways as a result of cross-reacting antibodies or immune complexes that bind to platelet receptors, or infection of progenitor megakaryocytes, and decreased production of thrombopoietin (TPO). It was shown that the vast majority of SLE patients with thrombocytopenia had increased levels of anti-glycoprotein IIb/IIIa (anti-GPIIb/IIIa) or anti-thrombopoietin receptor (anti-TPOR). Eltrombopag is a thrombopoietin receptor agonist that binds to the transmembrane portion of the surface receptor and induces maturation of megakaryocytes and production of platelets. Herein, we report two SLE patients with severe thrombocytopenia who are also refractory to both intravenous immunoglobulin (IVIG), rituximab, and splenectomy. Ultimately, they successfully treated with eltrombopag without any complication. Eltrombopag worked well and their platelet counts increased above 200,000/mm3 only two weeks later.



Cite this article as: Ulutaş F, Dündar Ök Z, Karasu U, Çobankara V. Successful Treatment of Systemic Lupus Erythematosus-Associated Thrombocytopenia with Eltrombopag: A Report of Two Cases and Literature Review. Mediterr J Rheumatol 2022;33(4):444-8.

Article Submitted: 20 Dec 2021; Revised Form: 5 Jun 2022; Article Accepted: 7 Jun 2022; Available Online: 31 Dec 2022

https://doi.org/10.31138/mjr.33.4.444

This work is licensed under a Creative Commons Attribution 4.0 International License.

©2022 The Author(s).